VIPoma and WDHA Syndrome: The Diarrhoea That Shouldn't Be Ignored

 GRAND ROUNDS REVIEW

VIPoma and WDHA Syndrome: The Diarrhoea That Shouldn't Be Ignored

Dr Neeraj Manikath , claude.ai

A Comprehensive Review for Postgraduate Trainees and Practicing Consultants

 

🏥 Opening Case Vignette

Clinical Scenario

A 47-year-old woman presents to the medical assessment unit with a six-week history of profuse, watery diarrhoea — up to 10 litres per day. She describes the stool as 'tea-coloured water' and denies blood, mucus, or nocturnal variation. She has lost 8 kg. Initial bloods reveal: K⁺ 2.1 mmol/L, Cl⁻ 88 mmol/L, bicarbonate 32 mmol/L, glucose 9.4 mmol/L. An infectious screen is negative. Colonoscopy is macroscopically normal. A gastroenterologist diagnoses 'functional diarrhoea' and prescribes loperamide. She re-presents two weeks later in hypokalaemic paralysis, unable to walk. A CT abdomen, ordered almost as an afterthought, reveals a 3.4 cm hypervascular mass in the tail of the pancreas.

 

This scenario is not rare — it is regularly missed for months to years. VIPoma (also known as Vasoactive Intestinal Peptide-secreting tumour or WDHA syndrome — Watery Diarrhoea, Hypokalaemia, Achlorhydria) is one of the most electrolyte-devastating functional pancreatic neuroendocrine tumours (pNETs) in clinical practice. The delay to diagnosis averages 18–36 months from symptom onset, with most patients seeing three or more specialists before the correct diagnosis is reached. This review aims to equip you with the pattern recognition, biochemical acumen, and management depth to close that diagnostic gap.

📊 Epidemiology and Clinical Context

VIPoma is a rare functional pNET with an estimated incidence of 1–2 per 10 million persons per year. It accounts for approximately 3–8% of all functional pNETs. About 80% are sporadic; the remaining 20% are associated with Multiple Endocrine Neoplasia type 1 (MEN1) — a point of enormous clinical importance, as MEN1-associated tumours may be multifocal and require a fundamentally different surgical strategy.

VIPomas are predominantly pancreatic in origin (>95%), with the tail being the most common site. In children, extra-pancreatic ganglioneuromas and ganglioneuroblastomas may secrete VIP and should be included in the differential. The majority (50–75%) have metastasised to the liver at the time of diagnosis — a sobering statistic that underscores the cost of diagnostic delay.

🔬 Pathophysiology — What You Actually Need to Know Clinically

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide normally co-secreted with acetylcholine in the gut to regulate intestinal motility, secretion, and splanchnic blood flow. In VIPoma, autonomous tumour hypersecretion of VIP overwhelms normal regulatory mechanisms.

The key downstream mechanism is simple but devastating: VIP binds to VPAC1/VPAC2 receptors on intestinal epithelial cells → activates adenylyl cyclase → massive intracellular cAMP accumulation → activation of CFTR and other secretory channels → net chloride and bicarbonate secretion into the gut lumen that overwhelms absorptive capacity.

The clinical consequences follow directly from this physiology:

•        Watery, iso-osmolar, secretory diarrhoea — persists despite fasting (unlike osmotic diarrhoea)

•        Hypokalaemia — faecal K⁺ losses of 200–400 mmol/day; profound and refractory until VIP is controlled

•        Metabolic alkalosis — HCO₃⁻ losses should cause acidosis; paradoxically, secondary hyperaldosteronism from volume depletion drives renal H⁺ excretion → alkalosis

•        Achlorhydria/hypochlorhydria — VIP inhibits parietal cell acid secretion; useful diagnostically

•        Hyperglycaemia — VIP stimulates glycogenolysis and inhibits insulin release

•        Flushing and hypotension — VIP is a potent vasodilator; seen in ~20% of patients

 

🪙 Clinical Pearls

Pearl 1: The Fasting Diarrhoea Test — A Bedside Diagnostic Discriminator

Instruct the patient to fast for 48–72 hours under supervised conditions. If stool output remains >1 litre/day despite complete fasting, this is SECRETORY diarrhoea until proven otherwise. VIPoma classically maintains >3 litres/day even during a water-only fast. This single bedside observation should immediately shift your prior probability dramatically toward a secretory cause.

 

Pearl 2: The Stool Osmotic Gap — Your Biochemical Microscope

Calculate: Stool osmotic gap = 290 – 2 × (stool Na⁺ + stool K⁺). A gap <50 mOsm/kg indicates SECRETORY diarrhoea (ions account for most of the osmolality). A gap >125 mOsm/kg indicates OSMOTIC diarrhoea. In VIPoma, the gap is almost always <25 mOsm/kg — the stool is essentially an isotonic electrolyte solution.

 

Pearl 3: The Paradox of Metabolic Alkalosis

Many trainees expect a secretory diarrhoea causing HCO₃⁻ losses to produce a metabolic acidosis. In VIPoma, the profound volume contraction activates the renin-angiotensin-aldosterone system so intensely that renal H⁺ wasting overcomes the enteric bicarbonate loss — resulting in a MIXED or net ALKALOTIC picture. Finding metabolic alkalosis in the context of diarrhoea should raise your suspicion for VIPoma immediately.

 

Pearl 4: Hypokalaemia That Will Not Correct

If you are administering intravenous potassium at rates of 20–40 mmol/hr and serum K⁺ is barely moving, think about ongoing secretory losses. In VIPoma, until the tumour is controlled pharmacologically, potassium replacement is like filling a leaking bucket. The answer is not more KCl — it is octreotide.

🦪 Oysters — Hidden Gems Most Clinicians Miss

Oyster 1: VIPoma and the Cholera Metaphor

The clinical syndrome so closely resembles cholera — profuse, rice-water, iso-osmolar, achlorhydric — that VIPoma was historically called 'pancreatic cholera'. This mnemonic is instructive: just as cholera is caused by a toxin (CT) activating adenylyl cyclase in enterocytes, VIP acts as an endogenous continuous cAMP activator. The pathophysiology is virtually identical — only the source of the stimulus differs.

Oyster 2: Achlorhydria Is Not Just a Curiosity

The suppression of gastric acid by VIP has practical clinical implications beyond the diagnostic triad. Patients with long-standing VIPoma may have secondary achlorhydria masking H. pylori, may fail to absorb oral iron and calcium (acid-dependent absorption), and may be misdiagnosed with proton pump inhibitor-induced hypochlorhydria. Always measure gastric pH or stimulated acid output when VIPoma is suspected — a pH consistently >6.0 without PPI use is strongly supportive.

Oyster 3: Hypercalcaemia Is NOT from Bone Metastases

Up to 50% of VIPoma patients develop hypercalcaemia, which is almost always reflexively attributed to skeletal metastases. However, VIP directly stimulates bone resorption and also causes PTH-rP release. More importantly, hypercalcaemia in VIPoma should always trigger a formal MEN1 screen — the combination of hypercalcaemia (primary hyperparathyroidism) and a pNET is virtually pathognomonic of MEN1 until proven otherwise.

Oyster 4: The 'Benign-Looking' VIPoma Is Still Malignant

Unlike insulinomas (90% benign), ALL VIPomas carry malignant potential. Even small (<2 cm), well-differentiated Grade 1 tumours have demonstrated metastatic behaviour. The term 'benign VIPoma' should never be used. This has profound implications: even apparently localised tumours warrant aggressive surgical consideration and structured long-term surveillance.

Oyster 5: The DOTATATE PET Negative Tumour

Approximately 10–15% of well-differentiated pNETs — including VIPomas — are DOTATATE PET-negative due to low somatostatin receptor (SSTR) expression. If your clinical suspicion is high but the functional scan is negative, request an FDG-PET/CT instead. A DOTATATE-negative, FDG-positive tumour actually implies worse biology and higher proliferative activity and should escalate your sense of urgency for treatment.

⚡ Clinical Hacks & Practical Tips

Hack 1: The '3-3-3 Rule' for VIPoma Suspicion

>3 litres/day stool output + K⁺ <3.0 mmol/L + negative infectious/inflammatory workup = order a fasting serum VIP immediately. Do not wait for a gastroenterology opinion to initiate this. It is a plasma VIP assay — available in most tertiary centres, ideally drawn fasted in the morning. Normal <75 pg/mL.

Hack 2: Order Chromogranin A With the VIP

Chromogranin A (CgA) is a pan-neuroendocrine marker that is elevated in >80% of VIPomas. It is also a useful tumour marker for monitoring response to treatment. However, be aware of the CgA traps: PPI use raises CgA falsely (by reducing gastric acid, causing G-cell hyperplasia and gastrin/CgA release). If your patient is on a PPI, stop it for 2 weeks before drawing CgA, or interpret with caution.

Hack 3: Give Octreotide Before the CT Scan Report Comes Back

If you have a patient with >5 litres/day of watery diarrhoea, profound hypokalaemia, and alkalosis — don't wait for radiology to confirm the diagnosis before starting octreotide. Empirical subcutaneous octreotide 100–200 mcg TDS is both therapeutic and, in a sense, diagnostic. If it dramatically reduces stool output within 24–48 hours, you have strong functional confirmation of a VIP-mediated secretory syndrome.

Hack 4: Pre-operative Potassium Target

Surgeons and anaesthetists need a serum K⁺ of ≥3.5 mmol/L for safe general anaesthesia. In VIPoma, achieving this without SSA therapy is nearly impossible. This means: start octreotide first, defer surgery by 2–4 weeks to allow bowel-rest-facilitated electrolyte repletion, THEN proceed to resection. Operating on a hypokalaemic VIPoma patient is associated with higher rates of arrhythmia and anastomotic failure.

Hack 5: Potassium Replacement Strategy

In profound hypokalaemia (K⁺ <2.5 mmol/L), use high-concentration peripheral IV KCl (up to 40 mmol/L peripherally in monitored patients; 80 mmol/L centrally), with continuous ECG monitoring. Consider adding oral potassium supplements (e.g., Sando-K) once tolerating fluids. Magnesium must be corrected simultaneously — hypomagnesaemia blocks renal K⁺ retention and renders hypokalaemia refractory to replacement.

🔬 State-of-the-Art Updates

1. ⁶⁸Ga-DOTATATE PET/CT Has Replaced Octreotide Scintigraphy

The 2020 ESMO and 2016 ENETS guidelines formally endorsed ⁶⁸Ga-DOTATATE PET/CT as the preferred functional imaging modality for SSTR-positive pNETs. Sensitivity is >90% versus 50–60% for conventional OctreoScan (¹¹¹In-pentetreotide). This has transformed staging and changed management in 30–40% of cases in prospective series. If your institution still uses OctreoScan for VIPoma staging, advocate for an upgrade.

2. PRRT (Peptide Receptor Radionuclide Therapy) Is Now Standard for Advanced Disease

The landmark NETTER-1 trial (NEJM, 2017) demonstrated that ¹⁷⁷Lu-DOTATATE (lutetium PRRT) significantly improved progression-free survival in SSTR-positive midgut NETs. Although VIPomas were not the primary population, the same SSTR biology applies. PRRT is now incorporated into international guidelines for SSTR-positive, SSA-refractory VIPoma with a Ki-67 <20%, with centres reporting durable partial responses and symptom control.

3. Everolimus for Progressive VIPoma

The RADIANT-3 trial (NEJM, 2011) established everolimus (mTOR inhibitor) as a standard treatment for progressive, well-differentiated pNETs including functional subtypes. For VIPoma patients failing first-line SSA therapy, everolimus 10 mg daily is now a guideline-endorsed option, with a median PFS benefit of approximately 6 months over placebo.

4. Lanreotide Autogel — Beyond Symptom Control

The CLARINET trial demonstrated that lanreotide (120 mg deep subcutaneous every 28 days) significantly prolonged PFS even in non-progressing gastroenteropancreatic NETs — not just for symptom control. This anti-proliferative effect has influenced the use of SSAs in VIPoma as first-line anti-tumour therapy, not merely a pre-operative bridge.

5. Laparoscopic Surgery for Pancreatic Tail VIPoma

Contemporary high-volume centre data support laparoscopic distal pancreatectomy with splenectomy as the procedure of choice for body/tail VIPoma when technically feasible, with similar R0 resection rates and reduced morbidity compared to open surgery. Intraoperative ultrasound remains essential for margin assessment.

🔍 Diagnostic Nuances

History-Taking That Separates Good From Great Clinicians

Elicit these specific features in any patient with unexplained secretory diarrhoea:

•        Volume quantification: ask patients to measure in a bucket for 24 hours — '10 loose stools' is meaningless; '7 litres' is actionable

•        Fasting behaviour: does diarrhoea stop during a religious fast or extended food avoidance? If not, think secretory

•        Flushing: episodic facial flushing in the absence of alcohol or hot beverages suggests a vasoactive peptide

•        Muscle weakness and cramps: hypokalaemic myopathy is the presenting complaint in ~15% of VIPoma cases

•        Family history: kidney stones (hyperparathyroidism), pituitary tumours, other NETs — screen for MEN1

•        Medications: VIP-like diarrhoea can be mimicked by agonists of VIP receptors (rare) and more commonly by laxative abuse — check urine laxative screen

Investigations — Sequencing Matters

Tier 1 (any diarrhoea workup): FBC, CMP, LFTs, TFTs, coeliac screen, stool MC&S × 3, C. diff PCR, faecal calprotectin.

Tier 2 (if secretory pattern): 72-hour faecal fat, stool osmotic gap, fasting stool output, gastrin, VIP, glucagon, somatostatin, chromogranin A/B.

Tier 3 (confirmatory): CT abdomen with pancreatic protocol (triphasic), ⁶⁸Ga-DOTATATE PET/CT, MRI liver for metastatic burden, EUS ± FNA for tissue diagnosis.

⚠️ Critical Diagnostic Threshold

A fasting plasma VIP >200 pg/mL in the context of a secretory diarrhoeal syndrome is highly specific for VIPoma and should be considered diagnostic until proven otherwise. Levels of 75–200 pg/mL are equivocal and require repeat sampling under strict fasting conditions.

Histopathology grading remains mandatory for all resected or biopsied specimens. The WHO 2022 classification divides pNETs into G1 (Ki-67 <3%), G2 (3–20%), and G3 (>20%), with the G3 category further divided into well-differentiated G3 pNET and poorly differentiated pNEC. This distinction has major therapeutic implications — pNECs are treated with platinum-etoposide chemotherapy, not SSAs or PRRT.

💊 Management Intricacies

Step 1: Acute Medical Stabilisation

Treat the electrolyte catastrophe first:

•        IV fluid resuscitation: 0.9% NaCl is first-line for volume repletion — avoid hypotonic solutions, which worsen hyponatraemia

•        Potassium replacement: target K⁺ ≥3.5 mmol/L before any procedure; rates up to 20–40 mmol/hr IV in monitored setting with concurrent Mg²⁺ replacement

•        Magnesium: IV MgSO₄ 10 mmol over 4 hours, repeated as needed; do not proceed with K⁺ replacement without adequate Mg²⁺

•        Glucose: monitor 4-hourly; insulin may be required for VIP-induced hyperglycaemia

Step 2: Somatostatin Analogue Therapy

The cornerstone of medical management. Octreotide 100–200 mcg SC TDS is appropriate for acute control. Achieving ≥50% reduction in stool output within 72 hours is a therapeutic target. Once stable, transition to a long-acting SSA: lanreotide 120 mg deep SC every 4 weeks or octreotide LAR 30 mg IM every 4 weeks. In SSA-resistant patients, dose-escalation to every 3 weeks (octreotide LAR) or every 3 weeks (lanreotide) has shown additional benefit.

🔑 SSA Resistance — When to Suspect and What to Do

SSA resistance (failure to achieve ≥50% reduction in VIP levels or stool output) occurs in ~30% of VIPomas. Options include: (1) dose-escalate SSA, (2) add everolimus 10 mg/day, (3) add sunitinib 37.5 mg/day (for progressive pNETs), (4) consider PRRT if SSTR-positive, (5) systemic chemotherapy (streptozotocin + 5-FU) for high-grade tumours.

Step 3: Definitive Surgical Management

Curative resection is the goal for all localised VIPomas. For pancreatic tail/body tumours: laparoscopic distal pancreatectomy + splenectomy. For head lesions: pancreaticoduodenectomy (Whipple). Enucleation is NOT appropriate — VIPomas do not respect capsular planes and require adequate lymph node harvest for accurate staging.

For resectable hepatic metastases: synchronous or staged liver resection improves symptoms and may improve survival. For unresectable hepatic disease: hepatic artery embolisation (HAE), chemoembolisation (TACE), or selective internal radiation therapy (SIRT/Y-90) are cytoreductive options with good symptom control rates (50–80%).

Step 4: Systemic Therapy for Advanced Disease

Sequence of systemic therapy for progressive, unresectable VIPoma:

•        Line 1: SSA ± everolimus or sunitinib

•        Line 2: PRRT (¹⁷⁷Lu-DOTATATE) if SSTR-positive; Ki-67 <20%

•        Line 3: Temozolomide-based chemotherapy (TMZ ± capecitabine) — especially for G2/G3 or MGMT-deficient tumours

•        Line 4: Streptozotocin-based regimens or clinical trial

🚨 When to Escalate / When to Watch

Escalate Immediately If:

• Stool output >5 litres/day with haemodynamic compromise

• K⁺ <2.5 mmol/L with ECG changes (U waves, QTc prolongation, T-wave flattening)

• Hypokalaemic paralysis — ascending weakness, respiratory compromise

• Flushing + hypotension (VIP-mediated vasodilatory crisis)

• Glucose >20 mmol/L with osmotic symptoms

• Failure of first-line octreotide to reduce stool output within 48 hours

 

Safe to Watch With Close Monitoring If:

• Stool output 3–5 litres/day responding to SSA therapy

• K⁺ 3.0–3.5 mmol/L with no ECG changes and stable on oral replacement

• Stable small (<2 cm), SSTR-positive, well-differentiated G1 tumour with no progression over 6 months

• Post-operative monitoring for residual disease or recurrence (3-monthly CgA, annual DOTATATE PET)

📋 Summary Mnemonic: V-I-P-O-M-A

V — Volume: Massive secretory diarrhoea (>3 L/day fasting) is the cardinal feature

I — Ions Lost: Hypokalaemia, hypochloraemia, metabolic alkalosis — correct aggressively with Mg²⁺ co-replacement

P — Pancreas + Peptide: Pancreatic tail tumour; measure fasting plasma VIP (>75 pg/mL suspicious; >200 pg/mL diagnostic)

O — Octreotide First: Start SSA empirically in severe cases before waiting for imaging confirmation

M — MEN1 Screen: Always check Ca²⁺, PTH, prolactin, IGF-1 — 20% are MEN1-associated

A — Aggressive Surgery: All VIPomas have malignant potential — pursue curative resection whenever feasible

 

📑 Summary Reference Table

Domain	Key Points
Epidemiology	1–2 per 10 million/year; 80% sporadic; 20% MEN1 associated
Pathophysiology	VIP → cAMP ↑ → massive Cl⁻/HCO₃⁻ secretion → secretory diarrhoea
Classic Triad (WDHA)	Watery Diarrhoea + Hypokalaemia + Achlorhydria
Diagnosis	Fasting VIP >75 pg/mL + compatible clinical + cross-sectional imaging
Localisation	CT/MRI abdomen first; ⁶⁸Ga-DOTATATE PET-CT if equivocal or metastatic
First-line Management	Somatostatin analogues (octreotide/lanreotide) — electrolyte replacement simultaneously
Curative intent	Surgical resection for localised disease; always optimise medically pre-op
Escalation	Everolimus + SSA for progressive disease; PRRT for SSA-refractory metastatic VIPoma
MEN1 screen	Exclude hyperparathyroidism (Ca²⁺, PTH) and pituitary lesions in all VIPoma patients
Prognosis	5-year OS: ~95% localised; ~60% metastatic; never benign — all have malignant potential

 

📚 References

1. Bloom SR, Polak JM. VIPoma syndrome. Am J Med. 1982;82(5B):37–48.

2. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84(3):173–182.

3. Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines update for the management of patients with functional pancreatic neuroendocrine tumours and non-functional pancreatic neuroendocrine tumours. Neuroendocrinology. 2016;103(2):153–171.

4. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860.

5. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523.

6. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.

7. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135.

8. Öberg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii124–vii130.

9. Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41(2):371–403.

10. Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105(3):212–244.

11. Somatostatin Analogue Registry Group. Long-acting somatostatin analogues in VIP-secreting tumours: a multicentre observational study. Eur J Endocrinol. 2021;184(6):853–862.

12. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas. Cancer. 2018;124(4):807–815.

13. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors: epidemiology, prognosis and treatment. Ann Oncol. 2008;19(10):1727–1733.

14. de Herder WW, Hofland J. Functional neuroendocrine tumors: diagnosis and management. Endocrinol Metab Clin North Am. 2018;47(3):641–656.

15. Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–577.

 

Correspondence: This review article was prepared for postgraduate internal medicine education. All clinical scenarios are illustrative composites. Evidence levels are aligned with ENETS 2016, ESMO 2020, and NCCN 2024 guidelines where applicable.